title: Immunonutrition in kidney and liver transplant recipients.
abstract: The immunonutrients arginine and omega-3 fatty acids decrease adverse outcomes after solid organ transplant in humans and experimental animals. Kidney transplant recipients who received daily supplements with arginine (9 g) and canola oil (30 mL) had significantly lower frequencies of complications between 30 days to 3 years than transplant recipients who did not receive supplements. In another study in kidney transplant recipients, arginine combined with either canola oil or fish oil was safe, effective, and provided good protection against rejection in patients who had steroid-free immunosuppression. In the 27 patients (50%) who had omega-3 index (percent omega-3 component of all fatty acids in red blood cell membranes) > 6 there was no acute rejection by 1 year after transplant; in 27 patients who had omega-3 index < 6, there were 5 patients (19%) who had acute rejection (P ≤ .01). No studies are available in liver transplant patients that have provided adequate doses or duration of immunonutrients. A prospective, randomized, double-blind clinical trial using immunonutrients is proposed for patients having primary liver transplant. In summary, immunonutrition in kidney transplant recipients with high doses of oral arginine and omega-3 fatty acids is effective, safe, and inexpensive, and may decrease the frequency of complications such as rejection, infection, new onset diabetes and cardiovascular disease. Further study with similar protocols in liver transplant recipients is justified.
authors.affiliation: Department of Surgery, University of Cincinnati College of Medicine and Shriners Hospital for Children, Cincinnati, OH, USA.
authors.forename: J Wesley
authors.initials: JW
authors.lastname: Alexander
mesh_terms: D000818:Animals; D001120:Arginine / Q000008:administration & dosage*; D019587:Dietary Supplements; D005229:Fatty Acids, Monounsaturated / Q000008:administration & dosage*; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage*; D006084:Graft Rejection / Q000276:immunology / Q000517:prevention & control*; D006085:Graft Survival / Q000187:drug effects; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000009:adverse effects; D016031:Liver Transplantation / Q000009:adverse effects; D009752:Nutritional Status; D000074262:Rapeseed Oil; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D005229:Fatty Acids, Monounsaturated; D015525:Fatty Acids, Omega-3; D007166:Immunosuppressive Agents; D000074262:Rapeseed Oil; D001120:Arginine